Stage of disease at diagnosis differed by IHC group (p=0.008), with 80% of ER-/PR-, HER2+ cancers presenting at Stage 4 compared to 35.6% of ER-/PR-, HER2- and 32% of ER+/PR+, HER2- cancers. The gene discussed is ERBB2; the disease is cancer.